Loss-of-function genetic screens with pooled sgRNA and shRNA libraries aid in discovery / prioritization of drug targets, understanding of disease progression and gene-disease associations, analysis of signal transduction pathways, characterization of the mechanisms for compounds, uncovering of synergistic gene interactions, and identification of markers of drug resistance and sensitivity. This webinar presents a comparison of loss-of-function genetic screens performed with CRISPR versus RNAi technology.